High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 7.4% in the afternoon session after the company unveiled Falcon, a new artificial intelligence platform for drug development, and announced several major global customer commitments.
Veeva Systems enters this update cycle with no changes to its existing price targets, which keeps the current analyst baseline intact for now. While there is no new analyst commentary to interpret, the absence of revisions can still tell you something about how expectations are holding steady. Read on to see how to track these kinds of quiet shifts so you can stay on top of the evolving narrative around the stock. Stay updated as the Fair Value for Veeva Systems shifts by adding it to your...
Veeva is on the verge of a technical breakout. The beaten-down biopharma software firm's growth outlook is strong, and it's a cash cow with a stellar balance sheet.
In recent days, Veeva Systems announced a string of major wins, including Kindeva Drug Delivery adopting Veeva Quality Cloud and Merck KGaA and Teva Pharmaceuticals committing globally to Veeva Vault CRM to unify quality and commercial operations. Together with the launch of its new Veeva Falcon agentic platform for drug development, these moves highlight Veeva’s push to embed specialized AI and cloud tools deeper into life sciences workflows. We’ll now examine how Veeva’s deeper integration...
Veeva Systems Inc. (NYSE:VEEV), with significant hedge fund interest, ranks among the 10 best SaaS stocks to buy according to hedge funds. As of Q1 2026, 62 hedge funds held bullish positions in the stock, representing $2.95 billion in aggregate value, as per Insider Monkey data. This week, Veeva Systems Inc. (NYSE:VEEV) is accelerating its […]
Veeva Systems Inc. (NYSE:VEEV) is one of the Best Wide Moat Stocks to Buy According to Wall Street Analysts. On May 28, the company announced that Kindeva is adopting Veeva Quality Cloud in a bid to modernize its manufacturing operations. This will help bring together the global network of sites onto the single cloud platform. With Veeva QualityDocs, Veeva QMS, Veeva […]
VEEV and IQV are benefiting from life sciences digitization trends, but differences in growth, AI adoption and valuation set them apart.
Get a deeper insight into the potential performance of Veeva (VEEV) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 3.8% in the afternoon session after the company announced that Kindeva, a global contract development and manufacturing organization (CDMO), would adopt its Veeva Quality Cloud platform to modernize manufacturing operations.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
monday.com delivers cloud-based workflow solutions to a global client base, serving enterprises and institutions across multiple sectors.
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Phreesia (PHR) delivered earnings and revenue surprises of +150.00% and +0.51%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
VEEV's growing Vault CRM adoption and AI momentum, backed by major pharma wins, reinforce confidence in its long-term growth outlook.
MercadoLibre operates a leading e-commerce and fintech platform serving businesses and consumers across Latin America.
Investors may be wondering whether Veeva Systems, at around US$160 per share, now offers good value or still looks expensive compared to its fundamentals and peers. The stock is up 0.8% over the past week. It is down 2.2% over the past month, 27.0% year to date, 31.3% over the past year, 3.2% over three years and 45.0% over five years, which may influence how you think about risk and potential upside. Recent headlines around healthcare technology and software providers have kept attention on...
A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is structurally undermining the legacy SaaS business model.
Veeva Systems (VEEV) closed the most recent trading day at $158.27, moving 4.06% from the previous trading session.
The latest trading day saw Veeva Systems (VEEV) settling at $164.96, representing a +1.01% change from its previous close.
We just covered the Michael Burry Stock Portfolio: Top 8 Stock Picks in 2026 and Veeva Systems Inc. (NYSE:VEEV) ranks 3rd on this list. In April, Michael Burry told his followers on Substack that he had bought a position in Veeva Systems Inc. (NYSE:VEEV) that was slightly larger than a low normal position he had […]
VEEV benefits from RTSM traction with major pharma wins, strengthening its clinical software strategy and long-term R&D growth outlook.
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Veeva Systems Inc. (NYSE:VEEV) is among the 10 Stocks That Will Make You Rich Over the Next Decade. It is considered a high-quality, long-term growth stock given its robust return on capital, free cash flow margin, and 5-year revenue growth estimates. This is helping drive strong institutional interest in the company. According to Insider Monkey’s database […]
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
In early May 2026, Smith+Nephew announced it is unifying its quality management on Veeva Quality Cloud, adopting Veeva QualityDocs, QMS, and Training to manage controlled content, global processes, and more than 500,000 annual trainings. This expands Veeva’s footprint in medtech and highlights how deeply its cloud platform can become embedded in mission-critical, compliance-heavy workflows. We’ll now examine how Smith+Nephew’s move to Veeva Quality Cloud may reinforce Veeva’s AI-led CRM and...
A number of stocks fell in the morning session after the April PPI report sent Treasury yields to 10-month highs, with the 10-year yield rising to 4.49%.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.